Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rislenemdaz (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Sponsors Avalo Therapeutics; Cerecor

Most Recent Events

01 May 2017 Cerecor intends to present additional data from this trial at the American Society of Clinical Psychopharmacologists Annual Meeting, according to a company media release.
03 Jan 2017 Status changed from active, no longer recruiting to completed.
29 Nov 2016 Primary endpoint has not been met. (Change in Bech-6 from baseline), as reported in a Cerecor media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com